Investment Rating - The report maintains a positive outlook on the overseas pharmaceutical sector, particularly highlighting the recent developments in drug approvals and partnerships [1][5]. Core Insights - The 2025 National Medical Insurance Directory and the first version of the commercial health insurance innovative drug directory were released, adding 114 new drugs, including 111 new drugs approved within the last five years. The success rate for negotiations was 88.19% [1][6]. - Fosun Pharma's subsidiary has licensed an oral GLP-1 drug to Pfizer, with potential milestone payments totaling up to $15.85 billion [2][7]. - The report emphasizes the importance of ongoing clinical trials and the introduction of innovative drugs in the market, which are expected to drive growth in the pharmaceutical sector [10]. Summary by Sections Domestic Policy Developments - The 2025 National Medical Insurance Directory includes 114 new drugs, with 112 successfully negotiated from 127 that entered the bidding process. Most renewal drugs were renewed at original prices, with an average price reduction of 8.4% for 15 drugs [6][7]. Domestic Pharmaceutical Company Updates - Fosun Pharma's subsidiary has signed a licensing agreement with Pfizer for the global development and commercialization of an oral GLP-1R agonist, with an upfront payment of $150 million and potential milestone payments [2][7]. - The approval of clinical trials for HER2 monoclonal antibodies for breast cancer treatment has been granted, indicating progress in innovative cancer therapies [2][7]. - New clinical data for a BCL2 inhibitor was presented, showing promising efficacy and safety in treating various blood cancers [2][7]. Overseas Pharmaceutical Company Updates - Wave Life Sciences reported positive Phase I data for an siRNA drug targeting obesity, showing significant reductions in visceral fat and overall body fat [3][9]. - Structure Therapeutics announced positive results for its oral GLP-1 small molecule, demonstrating substantial weight loss in clinical trials [3][9]. - Roche received EU approval for a CD20 monoclonal antibody for treating lupus nephritis, marking a significant advancement in autoimmune disease therapies [3][9]. Investment Recommendations - The report suggests focusing on innovative drugs and companies with active business development opportunities, particularly those with promising clinical pipelines [10].

Core Viewpoint - The article discusses the recent update of China's National Medical Insurance Drug List, which includes 114 new drugs, highlighting the introduction of a commercial health insurance innovative drug directory alongside the basic insurance list, aiming to enhance patient access to innovative treatments and address gaps in drug coverage [6][13]. Group 1: New Drugs in the National Medical Insurance Directory - A total of 114 new drugs have been added to the directory, covering various treatment areas including 36 for tumors, 12 for chronic diseases, and 10 for rare diseases, with the number of class 1 new drugs increasing from 38 to 50, setting a new historical high [6][7]. - Notable "star drugs" include LuKangsa Tazhu (for tumors), Fluorazirase tablets, and Spilumab (for specific dermatitis), which will benefit a wide range of patients, including those with triple-negative breast cancer and chronic sinusitis [7][8]. Group 2: Financial Impact on Patients - The average price reduction for negotiated drugs has historically been around 60%, with 112 out of 127 drugs successfully negotiated this year, resulting in significant cost savings for patients [9]. - The introduction of Spilumab, priced at around 1,000 yuan per injection, is expected to significantly lower the financial burden on patients, making innovative treatments more accessible [9]. Group 3: Implementation Challenges - There are concerns regarding the "last mile" issue in drug availability at hospitals, as many negotiated drugs are still provided through external pharmacies, and hospitals may hesitate to prescribe these due to cost concerns [10][11]. - The new regulations require that hospitals must not limit the availability of negotiated drugs based on overall budget constraints, ensuring that these drugs are accessible to patients [11]. Group 4: Changes in the Drug Directory - This year, 29 drugs were removed from the directory due to being replaced or not produced, with a total of 467 drugs removed over the past eight years for similar reasons [12]. - A six-month transition period has been established for patients using drugs that are not renewed in the directory, ensuring continuity of care [12]. Group 5: Commercial Health Insurance Innovative Drug Directory - The newly established commercial health insurance innovative drug directory includes 19 drugs, focusing on high-value innovative treatments that cannot be covered by the basic insurance directory [13][15]. - The drugs in this directory are characterized by high innovation, significant clinical value, and the need for diverse payment options, with 50% being class 1 new drugs [15]. Group 6: Benefits for Patients - The commercial health insurance directory aims to provide a curated list of high-quality drugs, reducing the selection burden for insurance companies and potentially lowering costs for patients through reduced premiums or increased reimbursement rates [16]. - The integration of the commercial insurance directory with existing medical insurance systems is being explored to enhance patient experience and access to innovative treatments [16]. Group 7: Future Prospects and Challenges - The implementation of the commercial health insurance innovative drug directory is dependent on market mechanisms, with insurance companies determining the usage and timing of these drugs [19]. - Emphasis on actuarial pricing and collaboration between insurance companies and pharmaceutical firms is crucial for the sustainable rollout of these innovative drugs [19].

Policy Developments - The National Healthcare Security Administration (NHSA) explained the "dual catalog" for the 2025 medical insurance drug list, adding 114 new drugs, including 105 negotiated new drugs, 7 competitive bidding drugs, and 2 directly transferred from national procurement [1] - Among the new drugs, 111 are newly launched within the last five years, accounting for nearly 98%, with 50 being Class 1 new drugs, marking a historical high in both proportion and quantity [1] - The new drugs cover key treatment areas such as oncology, anti-infection, chronic diseases, rare diseases, and mental illnesses [1] - The NHSA also released the first commercial insurance innovative drug catalog, including 19 innovative drugs from 18 companies, with 9 being Class 1 new drugs, approximately 50% of the total [1] Drug and Device Approvals - Fuan Pharmaceutical's subsidiary received a drug registration certificate for injectable isavuconazole, indicated for treating invasive aspergillosis and mucormycosis in adult patients [2] - Zhendong Pharmaceutical's investee company, Longchuang Pharmaceutical, had its new drug application for a vaginal probiotic capsule accepted by the National Medical Products Administration [3] Capital Markets - Mingji Hospital Group passed the listing hearing on the Hong Kong Stock Exchange, with CICC and Citigroup as joint sponsors [4] - Yifang Bio announced plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [5] - Insilico Medicine received approval from the China Securities Regulatory Commission for its overseas IPO, planning to issue up to 108,894,000 shares [6] - Huatai Medical plans to repurchase shares with a total amount between 200 million and 250 million yuan, with a buyback price not exceeding 315 yuan per share [8] Industry Developments - Nanjing Pharmaceutical's subsidiary plans to invest 398 million yuan in a modern pharmaceutical logistics expansion project, with a construction period of approximately 35 months [9] - Buchang Pharmaceutical's subsidiary plans to establish a new company with a registered capital of 1 million yuan, aimed at expanding its business scope [10] - Fosun Pharma's subsidiary, Yaoyou Pharmaceutical, signed a licensing agreement with Pfizer for a GLP-1 receptor agonist, with potential payments totaling up to 158.5 million dollars based on sales milestones [11] Public Opinion Alerts - Rhein Biotech is planning a change in control and intends to acquire at least 80% of Beijing Jinkangpu's equity, with the stock expected to be suspended for up to 10 trading days starting December 10, 2025 [12]

Core Insights - The National Healthcare Security Administration (NHSA) held a conference on December 9, 2023, to discuss the 2025 Medical Insurance Drug List, attracting significant interest from various stakeholders, including over 23,000 online viewers [1][6]. Group 1: Drug List Adjustments - The basic medical insurance fund, exceeding 3 trillion yuan, is directly linked to the annual release of the National Medical Insurance Drug List [6]. - In 2025, 114 new drugs were added to the basic medical insurance list, with 111 being new drugs launched within the last five years, marking a record high in both proportion and quantity [7]. - The adjustment process for the drug list has become clearer, with specific phases for preparation, application, review, and negotiation [7]. Group 2: Misunderstandings in Drug Pricing - There are misconceptions regarding the negotiation process, particularly the belief that all drugs must reduce prices upon renewal; only 30 out of 178 drugs negotiated for renewal experienced an average price drop of 13.8% [8]. - The average price reduction for the 15 drugs that were renewed was only 8.4% [8]. Group 3: Commercial Health Insurance Innovations - The NHSA introduced the first Commercial Health Insurance Innovative Drug List, which involves a more complex review process, including a re-evaluation by a specialized expert group [9]. - Certain drugs, while deemed valuable by basic medical insurance experts, were not included in the commercial insurance list due to concerns over their insurability and management difficulties [10]. Group 4: Challenges in Implementation - The NHSA aims to leverage the "three exclusions" policy to facilitate drug inclusion in hospitals and encourage the design of insurance products targeting the innovative drug list [11]. - There are significant challenges in aligning commercial insurance products with the innovative drug list, including low efficiency in claims processing and insufficient coverage [12]. Group 5: Differentiated Innovation in Pharmaceuticals - The NHSA emphasizes the need for differentiated innovation in pharmaceuticals, urging companies to provide robust evidence, such as head-to-head clinical trial data, to support claims of being "best in class" [15][16]. - The selection of reference drugs for economic evaluation is crucial, requiring a comprehensive approach that considers multiple dimensions of comparison [16][17].

Core Insights - The new National Medical Insurance Directory and the first Commercial Health Insurance Innovative Drug Directory will be implemented nationwide starting January 1, 2026, showcasing the government's commitment to enhancing healthcare access [1] Group 1: National Medical Insurance Directory - Nine innovative drugs from the STAR Market have been included in the new National Medical Insurance Directory, highlighting the strength and vitality of innovative pharmaceutical companies [1] - The inclusion of products like Baiyue Shenzhou's Baihe An and Kaize Bai in the first Commercial Health Insurance Innovative Drug Directory provides broader payment pathways for cutting-edge treatments [1][4] Group 2: Innovative Drug Companies - Nearly 90% of STAR Market biopharmaceutical companies have received medical insurance support for their newly approved drugs, indicating a favorable environment for innovation [2] - Junshi Biosciences' drug, Junshida, is the only domestic PCSK9-targeted drug for statin-intolerant patients included in the new medical insurance directory [2] - Haichuang Pharmaceutical's first marketed drug, Hainan An, is set to launch in May 2025 for treating metastatic castration-resistant prostate cancer, with its inclusion in the 2025 medical insurance directory expected to enhance market promotion and patient accessibility [2] Group 3: Drug Development and Market Integration - New cancer drugs from companies like Shanghai Ailis and Yifang Biotech provide precise treatment options for major diseases, demonstrating the efficient integration of new drug reviews and medical insurance payments in China [3] - Successful renewal negotiations for innovative drugs from companies like Baiyue Shenzhou and Junshi Biosciences further expand medical insurance coverage, benefiting a wider patient population [5] Group 4: R&D Investment and Future Outlook - R&D investment among STAR Market innovative drug companies reached a new high in the first three quarters of 2025, with a year-on-year increase of over 10% and an R&D intensity of 42%, significantly surpassing the overall A-share level [6] - The continuous improvement and collaboration of support policies like medical insurance and commercial insurance are expected to foster the emergence of more world-class new drugs, contributing to the health of the Chinese population [6]

Core Viewpoint - The release of the commercial health insurance innovative drug directory addresses the issue of "can it be used" at the hospital level, but the "last mile" between high-priced innovative drugs and patients remains unconnected. To achieve seamless transformation from "policy text" to "patient benefit," three key barriers must be crossed [1][3]. Group 1: Release of the Directory - On December 7, 2025, the National Healthcare Security Administration officially released the first version of the "Commercial Health Insurance Innovative Drug Directory," incorporating 19 high-clinical-value, high-cost innovative drugs into the commercial health insurance payment framework for the first time at the national level [2]. - The directory includes 14 anti-tumor drugs (including all 5 CAR-T therapies available in China), 2 rare disease drugs, and 2 Alzheimer's disease new drugs, aligning with the current claims data of commercial health insurance, where malignant tumors are the most prevalent and costly disease area [2]. Group 2: Policy Support and Challenges - The commercial health insurance innovative drug directory is supported by policies that exempt the listed drugs from self-payment rate assessments, collection of alternative monitored varieties, and DRG payment scope, addressing the challenges hospitals face in using innovative drugs under cost control pressures [3]. - Despite the directory solving the "can it be used" issue, the connection between high-priced innovative drugs and patients still needs to be established, requiring standardization and universalization of the directory [3][4]. Group 3: Standardization and Payment Collaboration - The current directory serves as a guiding list rather than a mandatory coverage requirement for commercial insurance products, necessitating the promotion of core drugs in the directory as standard configurations in commercial health insurance, especially in inclusive "benefit insurance" products [4]. - The basic medical insurance market can leverage its large insured population to negotiate lower drug prices, but the fragmented nature of the commercial health insurance market poses challenges in forming a cohesive payment force to negotiate with pharmaceutical companies [4]. Group 4: Service Integration and Patient Experience - An ideal multi-tiered payment system should achieve seamless integration and instant settlement among basic medical insurance, commercial insurance, and patient out-of-pocket expenses, which currently requires patients to prepay and navigate complex claims processes [5]. - Commercial insurance accounts for only 7.7% of the overall payment for innovative drugs, indicating significant growth potential. Bridging the "last mile" between the 19 innovative drugs in the directory and patients requires coordinated efforts from government and market forces [5].

Core Insights - The National Healthcare Security Administration (NHSA) has officially released the first version of the "Commercial Health Insurance Innovative Drug Directory," incorporating 19 high-value, expensive innovative drugs into the commercial health insurance payment framework for the first time [1][2] - The introduction of this directory marks a significant step in improving China's multi-tiered medical security system and transforming the role of commercial insurance [1] Group 1: Directory Overview - The directory includes 19 drugs, of which 14 are anti-tumor drugs (including all 5 CAR-T therapies available in China), 2 are rare disease medications, and 2 are new drugs for Alzheimer's disease [1] - The structure of the directory aligns closely with current claims data from commercial health insurance, as malignant tumors are the most prevalent and costly disease area in China [1] Group 2: Policy Support - The drugs listed in the commercial health insurance innovative drug directory are exempt from self-payment rate assessments, do not fall under centralized procurement monitoring, and are not included in the Diagnosis-Related Group (DRG) payment scope, referred to as the "three exclusions" policy [2] - This policy alleviates the challenges hospitals face in using innovative drugs amid pressures from centralized procurement and DRG payment reforms [2] Group 3: Implementation Challenges - The transition from policy text to patient benefits requires overcoming three key barriers: standardization and inclusivity of the directory, payment coordination and bargaining power, and service fluidity and one-stop experience [2][3][4] - The current directory serves as a guiding list rather than a mandatory coverage requirement for commercial insurance products, necessitating efforts to make core drugs standard features in commercial health insurance, especially in inclusive "benefit insurance" products [3] Group 4: Payment and Service Integration - The commercial health insurance market is fragmented, with varying funding levels and coverage across different regions, which raises uncertainties about its ability to negotiate effectively with pharmaceutical companies [3] - Establishing a regional or national commercial insurance procurement coordination mechanism is essential for negotiating better drug prices and conditions, ensuring financial sustainability of coverage plans [3][4] - The ideal multi-tiered payment system should enable seamless integration and immediate settlement among basic medical insurance, commercial insurance, and out-of-pocket expenses, which currently requires patients to prepay and navigate complex claims processes [4]

Core Insights - The newly released commercial insurance innovative drug directory includes 19 drugs, with 6 specifically for rare diseases, addressing conditions such as neuroblastoma and Gaucher disease [1][3] - The directory aims to provide a reference for multi-tiered medical insurance systems, but attracting more commercial insurance participation remains a challenge [1][6] Summary by Sections Rare Disease Drug Inclusion - The innovative drug for short bowel syndrome, injection of teduglutide, is set to be the first GLP-2 analog approved in China, filling a long-standing gap in treatment options [3][4] - Gaucher disease, affecting approximately 3,000 patients in China, now has a locally developed enzyme replacement therapy, injection of velaglucerase alfa, included in the directory [5] Challenges in Commercial Insurance - The increasing pressure on basic medical insurance funds makes it unrealistic to rely solely on them for rare disease drug coverage, highlighting the need for commercial insurance products like Huiminbao [6][8] - Huiminbao has made strides in covering certain rare disease drugs, but the number of drugs and policies available for rare diseases still needs improvement [8] Future Directions - Experts suggest that a multi-tiered approach involving basic insurance, commercial insurance, and charitable support is essential for effective rare disease drug coverage [9][10] - The focus should shift from post-reimbursement to comprehensive service and long-term health management for rare disease patients [10]

黄心宇表示，之所以前述PD-1类药品没有纳入商保创新药目录，是因为它们和基本医保目录内的药品 有很强的替代性。 "目前基本医保目录内已有10款左右PD-1" "今年，一些PD-1类药品也申报了商保创新药目录，但最终都没有成功入选。"国家医保局医药服务管理 司司长黄心宇12月9日表示。 12月9日晚间，国家医保局在线播出2025年医保药品目录解读会。黄心宇在会上说，今年国家医保局共 收到了141个商保创新药目录的申报信息，涉及药品通用名141个，说明参与申报的药品都是独家产品， 最终有121种药品通过了形式审查。这121种目录外药品在进入专家评审阶段后，仅24种药品通过评审， 通过率不到20％。之后，在价格协商阶段，24种药品中有19种价格协商成功，最终被纳入商保创新药目 录。 "目前基本医保目录内已有10款左右PD-1了。"黄心宇透露。 他进一步表示，从今年基本医保目录中新增药品的治疗领域来分析，肿瘤药还是大头，共计新增纳入36 种肿瘤治疗药物。包括肿瘤药在内，这些基本医保目录内新增药品有三个共性特征：填补临床空白、同 类更优和更具性价比。 "今年也有好几款PD-1通过了（基本医保目录谈判）的专家评审，但也有 ...

Core Insights - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have released the new National Medical Insurance Directory and the first Commercial Health Insurance Innovative Drug Directory, set to be implemented nationwide from January 1, 2026 [1][2] Summary by Sections National Medical Insurance Directory - A total of 114 new drugs have been added to the National Medical Insurance Directory, with 111 of them being new products launched within the last five years, representing 97.3% of the new additions [2] - Among the new drugs, 50 are classified as Category 1 innovative drugs, with a success rate of 88%, an increase from 76% in 2024 [2] - The total number of drugs in the directory has increased to 3,253, including 1,857 Western medicines and 1,396 traditional Chinese medicines [2] Company Announcements - Several listed companies, including Heng Rui Medicine, Fosun Pharma, and Hai Si Ke, announced new drug inclusions or renewals in the updated National Medical Insurance Directory [3] - Heng Rui Medicine reported that 20 products/indications were included, with significant coverage across various diseases such as tumors and cardiovascular conditions [3][4] - Hai Si Ke's two Category 1 innovative drugs were included, with one being a new addition and the other a renewal [4] Commercial Health Insurance Innovative Drug Directory - The first Commercial Health Insurance Innovative Drug Directory includes 19 new drugs from 18 innovative pharmaceutical companies, with 9 being Category 1 innovative drugs [7] - Notably, five CAR-T products were included, representing over half of the CAR-T products available in China, which previously faced challenges in entering the insurance market due to high pricing [7][8] - The directory also includes treatments for rare diseases and high-profile conditions such as Alzheimer's disease, enhancing the complementarity with the basic medical insurance [7][10] Notable Drug Inclusions - The directory includes drugs for significant diseases such as triple-negative breast cancer and pancreatic cancer, as well as treatments for rare diseases like Gaucher disease [5][9] - In the diabetes sector, several domestic drugs were newly included, such as a long-acting GLP-1 receptor agonist [6] - Companies like Bei Hai Kang Cheng and Bai Ji Shen Zhou have also successfully included their innovative drugs in the Commercial Health Insurance Directory [9]